These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25672711)

  • 1. [Exon skipping approach to Duchenne muscular dystorphy].
    Takeda S
    Rinsho Shinkeigaku; 2014; 54(12):1071-3. PubMed ID: 25672711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
    Guncay A; Yokota T
    Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
    [No Abstract]   [Full Text] [Related]  

  • 4. Exon-skipping events in candidates for clinical trials of morpholino.
    Nakano S; Ozasa S; Yoshioka K; Fujii I; Mitsui K; Nomura K; Kosuge H; Endo F; Matsukura M; Kimura S
    Pediatr Int; 2011 Aug; 53(4):524-9. PubMed ID: 21342350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge.
    Wood MJ
    Sci Transl Med; 2010 Mar; 2(25):25ps15. PubMed ID: 20424011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
    Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
    Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
    Touznik A; Lee JJ; Yokota T
    Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
    Takeda S
    Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides.
    Bremmer-Bout M; Aartsma-Rus A; de Meijer EJ; Kaman WE; Janson AA; Vossen RH; van Ommen GJ; den Dunnen JT; van Deutekom JC
    Mol Ther; 2004 Aug; 10(2):232-40. PubMed ID: 15294170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exon skipping: a first in class strategy for Duchenne muscular dystrophy.
    Niks EH; Aartsma-Rus A
    Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances of treatment for Duchenne muscular dystrophy with exon skipping].
    Yang J; Zhang C
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Aug; 28(4):406-8. PubMed ID: 21811980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
    Takeshima Y
    Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Exon-Skipping Therapeutic Approach for the DMD Gene Based on Asymptomatic Deletions of Exon 49.
    Abaji M; Gorokhova S; Da Silva N; Busa T; Grelet M; Missirian C; Sigaudy S; Philip N; Leturcq F; Lévy N; Krahn M; Bartoli M
    Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35886062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon-skipping therapy for Duchenne muscular dystrophy.
    Nakamura A; Takeda S
    Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
    Aartsma-Rus A; van Ommen GJ
    RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.